Skip to main content

Advertisement

SpringerLink
Log in

Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Circulating angiogenic factors (CAF) have been shown as therapeutic targets and prognostic biomarkers in metastatic colorectal cancer. However, their correlation with circulating tumor cells (CTC) is unknown, as is their role as prognostic biomarkers in patients amenable for curative resection.

Methods

Preoperative blood samples were collected in patients undergoing potentially curative resection of colorectal liver metastases. Serum levels of eight CAF and CTC were analyzed by using ELISA and CK20 RT-PCR, respectively. Prognostic factors were identified by a Cox proportional hazards model.

Results

A total of 107 patients were eligible for final analyses. Circulating levels of PlGF, EGF, and bFGF were increased, whereas PDGF-A and Ang-1 levels were decreased in patients compared with healthy control subjects. CTC were detected in 36 of 63 patients (57%) and were associated with significantly lower levels of EGF and bFGF. On univariate analyses, multiple metastases (p = 0.04), a MSKCC risk score >2 (p = 0.004), and detection of CTC (p = 0.05) were associated with disease recurrence. Multivariate analysis, including the panel of eight CAF, revealed a MSKCC score >2 [hazard ratio (HR), 2.01; 95% confidence interval (CI), 1.11–3.82; p = 0.02] and low levels of circulating PlGF (HR, 0.26; 95% CI, 0.08–0.81; p = 0.02) as independent predictors of poor recurrence-free survival.

Conclusions

CAF may indicate patients who are at high risk for disease recurrence. The notion that CAF may identify patients who benefit from adjuvant therapy or antiangiogenic agents warrants further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Tomlinson JS, Jarnagin WR, Dematteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575-80.

    Article  PubMed  Google Scholar 

  2. Reissfelder C, Rahbari NN, Koch M, et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16:3279–88.

    Article  PubMed  Google Scholar 

  3. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440-8.

    PubMed  Google Scholar 

  4. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010;28:2300–9.

    Article  PubMed  CAS  Google Scholar 

  5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

    Article  PubMed  CAS  Google Scholar 

  6. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6:327–38.

    Article  PubMed  CAS  Google Scholar 

  7. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–74.

    Article  PubMed  CAS  Google Scholar 

  8. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453–9.

    Article  PubMed  CAS  Google Scholar 

  9. Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138:1714–26.

    Article  PubMed  Google Scholar 

  10. Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg. 2002;236:768–75.

    Article  PubMed  Google Scholar 

  11. Koch M, Kienle P, Kastrati D, et al. Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer. 2006;118:3072–7.

    Article  PubMed  CAS  Google Scholar 

  12. Koch M, Kienle P, Hinz U, et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg. 2005;241:199–205.

    Article  PubMed  Google Scholar 

  13. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213–21.

    Article  PubMed  Google Scholar 

  14. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.

    Article  PubMed  CAS  Google Scholar 

  15. Weitz J, Kienle P, Lacroix J, et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res. 1998;4:343–8.

    PubMed  CAS  Google Scholar 

  16. Weitz J, Kienle P, Magener A, et al. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin Cancer Res. 1999;5:1830–6.

    PubMed  CAS  Google Scholar 

  17. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207–25.

    PubMed  CAS  Google Scholar 

  18. De VF, Orditura M, Lieto E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer. 2004;100:270–8.

    Article  Google Scholar 

  19. Kumar H, Heer K, Lee PW, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 1998;4:1279–85.

    PubMed  CAS  Google Scholar 

  20. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol. 2000;26:657–62.

    Article  PubMed  CAS  Google Scholar 

  21. Kwon KA, Kim SH, Oh SY, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. 2010;10:203.

    Article  PubMed  Google Scholar 

  22. Poston GJ, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol. 2008;26:4828–33.

    Article  PubMed  Google Scholar 

  23. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6:2803–7.

    PubMed  CAS  Google Scholar 

  24. Tokunaga T, Oshika Y, Abe Y, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998;77:998–1002.

    Article  PubMed  CAS  Google Scholar 

  25. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998;78:1379–84.

    Article  PubMed  CAS  Google Scholar 

  26. Wei SC, Liang JT, Tsao PN, Hsieh FJ, Yu SC, Wong JM. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. Dis Colon Rectum. 2009;52:1630–6.

    Article  PubMed  Google Scholar 

  27. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer. 2009;125:1657–62.

    Article  PubMed  CAS  Google Scholar 

  28. Arun C, London NJ, Hemingway DM. Prognostic significance of elevated endothelin-1 levels in patients with colorectal cancer. Int J Biol Markers. 2004;19:32–7.

    PubMed  CAS  Google Scholar 

  29. Tsushima H, Ito N, Tamura S, et al. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res. 2001;7:1258–62.

    PubMed  CAS  Google Scholar 

  30. Zaman K, Driscoll R, Hahn D, et al. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer. 2006;118:755–64.

    Article  PubMed  CAS  Google Scholar 

  31. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004;101:2727–36.

    Article  PubMed  CAS  Google Scholar 

  32. Vidal O, Metges JP, Elizalde I, et al. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg. 2009;96:1443–51.

    Article  PubMed  CAS  Google Scholar 

  33. Yoon SS, Kim SH, Gonen M, et al. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 2006;13:353–62.

    Article  PubMed  Google Scholar 

  34. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575–83.

    Article  PubMed  CAS  Google Scholar 

  35. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936–43.

    Article  PubMed  CAS  Google Scholar 

  36. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831–40.

    PubMed  CAS  Google Scholar 

  37. Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell. 2002;1:99–108.

    Article  PubMed  CAS  Google Scholar 

  38. Xu L, Cochran DM, Tong RT, Winkler F, Kashiwagi S, Jain RK, Fukumura D. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res. 2006;66:3971–7.

    Article  PubMed  CAS  Google Scholar 

  39. Chang YT, Chang MC, Wei SC, et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas. 2008;37:145–50.

    Article  PubMed  CAS  Google Scholar 

  40. Pompeo E, Albonici L, Doldo E, Orlandi A, Manzari V, Modesti A, Mineo TC. Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thorac Surg. 2009;88:426–31.

    Article  PubMed  Google Scholar 

  41. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.

    Article  PubMed  CAS  Google Scholar 

  42. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009;9:639–51.

    Article  PubMed  CAS  Google Scholar 

  43. Asahara T, Bauters T, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic growth factor on angiogenesis in vivo. Circulation. 1995;92:365–71.

    CAS  Google Scholar 

  44. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998;141:1659–73.

    Article  PubMed  CAS  Google Scholar 

  45. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg. 2001;182:298–304.

    Article  PubMed  CAS  Google Scholar 

  46. Brattstrom D, Bergqvist M, Hesselius P, et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer. 2002;37:57–63.

    Article  PubMed  Google Scholar 

  47. Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine. 2002;20:184–90.

    Article  PubMed  CAS  Google Scholar 

  48. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol. 2004;15:1261–6.

    Article  PubMed  CAS  Google Scholar 

  49. Brattstrom D, Bergqvist M, Larsson A, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res. 1998;18:1123–7.

    PubMed  CAS  Google Scholar 

  50. Colomer R, Aparicio J, Montero S, Guzman C, Larrodera L, Cortes-Funes H. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer. 1997;76:1215–20.

    Article  PubMed  CAS  Google Scholar 

  51. Obermair A, Speiser P, Reisenberger K, et al. Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett. 1998;130:69–76.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany

    Nuh N. Rahbari MD, Christoph Reissfelder MD, Monika Mühlbayer MD, Kathrin Weidmann MD, Christoph Kahlert MD, Markus W. Büchler MD, Jürgen Weitz MD, MSc & Moritz Koch MD

Authors
  1. Nuh N. Rahbari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Reissfelder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monika Mühlbayer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kathrin Weidmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christoph Kahlert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus W. Büchler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jürgen Weitz MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Moritz Koch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nuh N. Rahbari MD.

Additional information

Nuh N. Rahbari and Christoph Reissfelder contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rahbari, N.N., Reissfelder, C., Mühlbayer, M. et al. Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases. Ann Surg Oncol 18, 2182–2191 (2011). https://doi.org/10.1245/s10434-011-1761-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-1761-9

Keywords

Search

Navigation